Healthcare engagement in the Asia-Pacific (APAC) region is increasingly shifting from traditional settings to digital platforms, patient forums, and social media feeds. Despite APAC accounting for over half of global social media users, its pharmaceutical sector…
Medical Science Liaisons (MSLs) serve as the bridge between pharmaceutical companies, healthcare professionals, and the scientific community. Their impact reverberates across the entire healthcare ecosystem as they are essential for fostering scientific dialogue, driving evidence-based medicine,…
As the needs of patients and healthcare providers evolve, it is essential to continuously adapt support services to meet these changing demands. Dive into our latest article, featuring insights from David Frey, Kevin O’Meara, and Lee…
In the excitement of global drug launches, a critical issue often overlooked is the lack of local clinical evidence in many Asia-Pacific countries. This gap forces healthcare providers to rely on Western data, which may not…
Mike Ryan, General Manager, Europe, at EVERSANA, connected in a conversation with PharmaShots before Reuters Pharma 2025 in Barcelona, which ran 9-11 April 2025. Mike’s discussion focused on the history of EVERSANA and how the company…
Are you gearing up for product launches and health technology assessment (HTA) submissions? Look no further! EVERSANA is proud to announce an exclusive course at the ISPOR Education Center, led by renowned experts Chris Cameron from…
Modernizing Clinical Trials to Accelerate Access Clinical trials are essential for bringing life-changing therapies to market, yet traditional models often present significant barriers for both participants and trial sites. A leading pharmaceutical manufacturer partnered with EVERSANA…
While randomized controlled trials (RCTs) have been instrumental in establishing new standards of care, a comprehensive understanding of treatment effectiveness requires insights from real-world evidence (RWE). This is particularly true in the evolving landscape of hormone…
Are you curious about the evolving landscape of generic substitution in Southeast Asia and other emerging markets? Our latest white paper, Generic Substitution in Southeast Asia and Emerging Markets: Key Insights for Strategic Decision-Making, delves into the…
As C-suite leaders in pharma wrestle with the pros and cons of launching alone, licensing or partnering with another company to launch their product, one factor they must consider is the impact their decision will have…